Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + trametinib versus dabrafenib + placebo in first-line BRAF V600E/K-mutant advanced melanoma
NL-OMON47344Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous melanoma (CM) comparing dabrafenib + trametinib with dabrafenib + placebo (2 arms). Primary endpoint: Progression-free survival. Started Jul 2012; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON47344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47344.